Unit with one of the most comprehensive oncology product portfolios on the market. It was a pioneer in making the first generic oncological product available on the Brazilian market.
See a complete list of oncology drugs
The oncological portfolio is broad and diversified. In 2015, the Fiprima® (filgrastim) was recorded, being the first biosimilar medicine in Latin America.
Created in 1996, the Unit has one of the most complete portfolios of oncology products in the market and has pioneered by providing the Brazilian market with the first generic oncological product. In 2010, the unit began marketing on an exclusive basis in the country, the CIMAher®, a monoclonal antibody for cancer treatment, shaping up as the first Brazilian pharmaceutical company to market this type of product in Brazil.
Eurofarma has a broad and diversified portfolio of oncological products. This Unit has reported a 22.1% revenue growth if compared to 2021, and a 73.3% volume increase. The highlight goes to the launch of a new drug, Nuvyor® (Lenalidomide), which marks its entry into the Hematology sector with the first similar equivalent available in the market.
Eurofarma holds the title as the company with the largest number of oncological drug molecules in the Brazilian market (31 molecules).